Anonymous
Guest
Anonymous
Guest
At last check, I think most orthopedic implant companies are running at margins of just over 75%. This is not uncommon in the market space we operate in. Having said this, I am still scared about the impact of competition comming to the markert place. How can we fight against a product at less than half our price?
Well, had our clinical affairs director been clinical and not an accountant, we might have studies that show clinical and economic benefit. Had we spent our money there instead of on developing products that do not come to market or are of little benefit ie; MBS, EVS, we may actually have a shot. But, not now!